학술논문
Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial
Document Type
Article
Author
Seekircher, L.; Tschiderer, L.; Willeit, P.; Bánki, Z.; Kimpel, J.; Rössler, A.; Schäfer, H.; Falkensammer, B.; Bante, D.; von Laer, D.; Borena, W.; Harthaller, T.; Forer, L.; Schönherr, S.; Sacher, M.; Ower, C.; Ulmer, H.; Krammer, F.; Neurauter, B.; Hochmuth, E.; Hoch, L.; Huber, M.; Müllauer, B.; Peer, E.; Raschbichler, L.-M.; Falch, A.; Embacher-Aichhorn, S.; Becker, K.
Source
In: The Lancet Microbe . (The Lancet Microbe, August 2023, 4(8):e612-e621)
Subject
Language
English
ISSN
26665247